Clinical Evaluation of Subantimicrobial-dose of Doxycycline Combined with Compound Acid in the Treatment of Moderate to Severe Acne
Objective To investigate the efficacy and safety of subantimicrobial-dose of doxycycline combined with compound acid in the treatment of moderate to severe acne.Methods From march 2021 to november 2022,a total of 90 patients with moderate to severe acne who was selected in the dermatology department of the author's hospital,and they were divided into A、B、C groups,with 30 cases in each group.Group A was given subdose(40 mg/d)doxycycline tablets combined with compound acid treatment,group B was given conventional dose(100 mg/d)doxycycline tablets combined with compound acid treatment,group C was given conventional dose(100 mg/d)doxycycline tablets,a total course of treatment for 12 weeks.The clinical effect,severity of acne,and adverse reactions of each group were compared.Results After treatment,the total effective rate of group A and B was significantly higher than that of group C(P<0.05).After 12 weeks of treatment,pimples,papules,pustules,cysts and nodular lesions in all groups were lower than before treatment.The results of comparison of clinical symptom scores and GAGS severity showed that there were significant differences between group A and Group C(P<0.05),while there was no statistical significance between group A and group B(P>0.05).The incidence of adverse reactions in group A was significantly lower than that in groups B and C(6.67%,83.33%,86.67%,P<0.05).The group C had a higher incidence of gastrointestinal adverse events.Conclusion The clinical effect of Subantimicrobial-dose of Doxycycline Combined with compound acids in the treatment of moderate and to severe acne is similar to that of conventional dose doxycycline combined with compound acid,but the adverse reactions of subantimicrobial-dose of doxycycline are low,especially the incidence of gastrointestinal reactions is lower,the tolerance of patients is high,and it has the use and promotion value.
acnemoderate to severedoxycyclinesubantimicrobial-dosecompound acidsafety